Study # ACE-Breast-03

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd

All Clinical Trials
Share on Facebook Share on X Share on LinkedIn Email

Study Description

Phase 2 study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd. The ARX788 will be administered every 3 weeks via intravenous (IV) infusion.